Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup - Archive ouverte HAL Access content directly
Journal Articles Science Translational Medicine Year : 2021

Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup

(1, 2, 3) , (1, 4) , (2, 3) , (1, 4) , (1) , (2, 3) , (2, 3) , (5) , (2, 3) , (5) , (6) , (7, 8, 9) , (10, 11) , (2, 3) , (1, 12) , (7, 8, 9) , (12, 1) , (2, 3)
1
2
3
4
5
6
7
8
9
10
11
12

Abstract

Adult "T cell" acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that is associated with poor outcomes, requiring additional therapeutic options. The DNA methylation landscapes of adult T-ALL remain undercharacterized. Here, we systematically analyzed the DNA methylation profiles of normal thymic-sorted T cell subpopulations and 143 primary adult T-ALLs as part of the French GRAALL 2003–2005 trial. Our results indicated that T-ALL is epigenetically heterogeneous consisting of five subtypes (C1-C5), which were either associated with co-occurring DNA methyltransferase 3 alpha (DNMT3A)/isocitrate dehydrogenase [NADP(+)] 2 (IDH2) mutations (C1), TAL bHLH transcription factor 1, erythroid differentiation factor (TAL1) deregulation (C2), T cell leukemia homeobox 3 (TLX3) (C3), TLX1/in cis-homeobox A9 (HOXA9) (C4), or in trans-HOXA9 overexpression (C5). Integrative analysis of DNA methylation and gene expression identified potential cluster-specific oncogenes and tumor suppressor genes. In addition to an aggressive hypomethylated subgroup (C1), our data identified an unexpected subset of hypermethylated T-ALL (C5) associated with poor outcome and primary therapeutic response. Using mouse xenografts, we demonstrated that hypermethylated T-ALL samples exhibited therapeutic responses to the DNA hypomethylating agent 5-azacytidine, which significantly (survival probability; P = 0.001 for C3, 0.01 for C4, and 0.0253 for C5) delayed tumor progression. These findings suggest that epigenetic-based therapies may provide an alternative treatment option in hypermethylated T-ALL.
Fichier principal
Vignette du fichier
Touzart_Sience Translation Medicine_Accepted version.pdf (9.22 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03282998 , version 1 (14-02-2022)

Identifiers

Cite

Aurore Touzart, Anand Mayakonda, Charlotte Smith, Joschka Hey, Reka Toth, et al.. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Science Translational Medicine, 2021, 13 (595), pp.eabc4834. ⟨10.1126/scitranslmed.abc4834⟩. ⟨hal-03282998⟩
253 View
232 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More